Table 1.
Select Model Inputs
| Parameter | Estimate | Data Source Used in Derivations | ||||
|---|---|---|---|---|---|---|
| Cohort Characteristics
| ||||||
| Demographics | Mean (SD) or Percent | Lane et al. 201017 | ||||
| Mean Age | 58.7 (7.9) | |||||
| Percent Female | 59% | |||||
| Percent White | 88% | |||||
| Percent K-L 2 | 30% | |||||
| Percent K-L 3 | 53% | |||||
| WOMAC Pain | 67(13) | |||||
| Starting WOMAC Pain | ||||||
| 15–40 | 41–70 | 71+ | ||||
|
|
||||||
| Percent of Cohort | 2% | 58% | 41% | |||
|
| ||||||
| Quality of Life Utilities (Nonobese/Obese) | WOMAC Pain (0–100) | Osteoarthritis Initiative38 | ||||
| 0 Comorbidities | Brazier et al. 200439 | |||||
|
|
||||||
| Age Group | 0 | 1–15 | 16 – 40 | 41 – 70 | 71 – 100 | |
|
|
||||||
| 25–44 | 0.865/0.845 | 0.840/0.820 | 0.781/0.761 | 0.699/0.679 | 0.609/0.589 | |
| 45–54 | 0.841/0.830 | 0.816/0.806 | 0.780/0.769 | 0.714/0.703 | 0.656/0.645 | |
| 55–64 | 0.847/0.836 | 0.822/0.812 | 0.786/0.775 | 0.720/0.709 | 0.662/0.651 | |
| 65–74 | 0.871/0.860 | 0.846/0.835 | 0.810/0.799 | 0.744/0.733 | 0.685/0.675 | |
| 75+ | 0.854/0.843 | 0.829/0.818 | 0.793/0.782 | 0.727/0.716 | 0.669/0.658 | |
| 1 Comorbidity | ||||||
|
|
||||||
| Age Group | 0 | 1–15 | 16 – 40 | 41 – 70 | 71 – 100 | |
|
|
||||||
| 25–44 | 0.845/0.825 | 0.820/0.800 | 0.761/0.741 | 0.679/0.659 | 0.589/0.569 | |
| 45–54 | 0.818/0.807 | 0.791/0.780 | 0.755/0.744 | 0.679/0.668 | 0.645/0.634 | |
| 55–64 | 0.824/0.813 | 0.797/0.786 | 0.761/0.750 | 0.685/0.674 | 0.651/0.640 | |
| 65–74 | 0.848/0.837 | 0.821/0.810 | 0.785/0.774 | 0.708/0.698 | 0.674/0.664 | |
| 75+ | 0.831/0.820 | 0.804/0.793 | 0.768/0.757 | 0.692/0.681 | 0.658/0.647 | |
| 2+ Comorbidities | ||||||
|
|
||||||
| Age Group | 0 | 1–15 | 16 – 40 | 41 – 70 | 71 – 100 | |
|
|
||||||
| 25–44 | 0.825/0.805 | 0.800/0.780 | 0.741/0.721 | 0.659/0.639 | 0.569/0.549 | |
| 45–54 | 0.806/0.795 | 0.794/0.783 | 0.732/0.721 | 0.635/0.624 | 0.500/0.489 | |
| 55–64 | 0.812/0.801 | 0.800/0.789 | 0.738/0.727 | 0.641/0.630 | 0.506/0.495 | |
| 65–74 | 0.836/0.825 | 0.824/0.813 | 0.762/0.751 | 0.665/0.654 | 0.530/0.519 | |
| 75+ | 0.819/0.808 | 0.807/0.796 | 0.745/0.734 | 0.648/0.637 | 0.513/0.502 | |
|
| ||||||
| Underlying Medical Costs | Comorbidities | Pope et al 201441 NHANES 2009–201233 MCBS 200943 Red Book Online53 CPI63 |
||||
| Age group | 0–1 | 2–3 | 4+ | |||
|
|
||||||
| 25–34 | $1,400 | $7,500 | $14,300 | |||
| 35–44 | $2,000 | $8,000 | $14,300 | |||
| 45–49 | $2,700 | $8,200 | $14,300 | |||
| 50–54 | $2,700 | $8,200 | $14,300 | |||
| 55–59 | $3,500 | $8,800 | $14,700 | |||
| 60–64 | $4,300 | $9,600 | $15,500 | |||
| 65–69 | $4,600 | $9,900 | $15,500 | |||
| 70–74 | $5,300 | $10,700 | $16,200 | |||
| 75–79 | $6,200 | $11,600 | $17,100 | |||
| 80+ | $8,200 | $13,500 | $19,100 | |||
|
| ||||||
|
Tanezumab Treatment Characteristics
| ||||||
| Annual Cost (2014 USD) | Drug Cost | Administrative Cost | Monitoring Cost | |||
| First Year | 200, 400, 600, 800, 1000 | 61, 69, 133, 241, 433 | 277, 495 | |||
| Subsequent Years | 200, 400, 600, 800, 1000 | 0, 69, 133, 241, 433 | 277, 495 | Medicare Fee Schedules49 | ||
|
| ||||||
| Pain Relief | Starting Pain | |||||
|
|
||||||
| 15–40 | 41–70 | 71+ | ||||
|
|
||||||
| Mean (SD) Pain Reduction | 13 (16) | 29 (18) | 41 (18) | Lane et al 201017 | ||
| Late Failure Rate (%) | 10 | - | - | Klareskog et al. 200645 | ||
| Max Years Efficacy | 15 | - | - | Assumption | ||
|
| ||||||
| Adverse Effects | Minor Toxicity | Major Toxicity | ||||
| First Year Rate (%) | 60 | 1 | Hochberg et al. 201548 | |||
| Subsequent Years Rate (%) | 30 | 0.5 | ||||
| QOL Multiplier | 0.997 | 0.59 | ||||
| Cost (2014 USD) | 52 | 137 | ||||
*
In 2014 USD. Values exclude as needed pain management. An annual cost of $102 was added for patients with symptomatic knee OA
**
Minor toxicity disutility and cost based on NSAID toxicity characteristics. Rate of minor toxicity was assumed. Major toxicity cost based on additional physician office visits and x-rays to diagnose rapid OA progression. Major toxicity disutility calibrated to yield QOL of 0.5 immediately prior to TKR following rapid OA progression.